Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Documenti analoghi

• Characterization of Lewy Body copathology in early AD clinical trial population demonstrates similarities and differences compared to natural history studies in Alzheimer's disease patients
  di: David Verbel, et al.
  Pubblicazione: (2025)
• Identifying differentially expressed proteins between amyloid positive and amyloid negative subjects based on Alamar multiplex assay data using MissionAD samples
  di: Pallavi Sachdev, et al.
  Pubblicazione: (2025)
• Unexpected Low Rate of Amyloid‐β Pathology in Multiple Sclerosis Patients
  di: Matthew R. Brier, et al.
  Pubblicazione: (2024)
• What Are "Adult Services"?
  di: Wente, Joyce
  Pubblicazione: (1979)
• Bayesian inference for near-field interferometric tests of collapse models
  di: Laing, Shaun, et al.
  Pubblicazione: (2023)